Comparison of receptor mechanisms and efficacy requirements for δ-agonist-induced convulsive activity and antinociception in mice

被引:69
作者
Broom, DC
Nitsche, JF
Pintar, JE
Rice, KC
Woods, JH
Traynor, JR
机构
[1] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Psychol, Ann Arbor, MI USA
[3] Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ USA
[4] NIDDKD, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1124/jpet.102.036525
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
delta-Opioid receptor-selective agonists produce antinociception and convulsions in several species, including mice. This article examines two hypotheses in mice: 1) that antinociception and convulsive activity are mediated through the same type of delta-receptor and 2) that greater delta-agonist efficacy is required for antinociception than for convulsive activity. delta-Mediated antinociception was evaluated in the acetic acid-induced abdominal constriction assay, which involves a low-intensity noxious stimulus; convulsive activity was indicated as a mild tonic-clonic convulsive episode followed by a period of catalepsy. In delta-opioid receptor knockout mice [DOR-1(-/-)], the nonpeptidic delta-agonists (+/-)-4-[( R*)-[(2S*, 5R*)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-( 3-hydroxyphenyl) methyl]- N,N- diethylbenzamide hydrochloride (BW373U86) and (+)-4-[(R)-[(2S, 5R)-2,5-dimethyl- 4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl) methyl]- N, N-diethylbenzamide (SNC80) failed to produce convulsive behavior demonstrating the absolute involvement of DOR-1 in this effect. In NIH Swiss mice expressing delta-opioid receptors, BW373U86 produced both antinociception and convulsive activity. These effects were antagonized by the putative delta(1)-receptor-selective antagonist 7-benzylidenenaltrexone and the putative delta(2)-receptor-selective antagonist naltriben. Tolerance developed to both the convulsive and antinociceptive effects of BW373U86. Tolerance to the convulsive, but not the antinociceptive, effects of BW373U86 was largely prevented when the antagonist naltrindole was given 20 min after each dose of the agonist in a 3-day treatment paradigm. The convulsive action of BW373U86 was also less sensitive than the antinociceptive action to treatment with the irreversible delta-antagonist naltrindole isothiocyanate. Collectively, these data suggest that the convulsive and antinociceptive activities of delta-agonists are mediated through the same receptor but that the receptor reserve for delta-mediated convulsive activity is greater than for delta-mediated antinociceptive activity.
引用
收藏
页码:723 / 729
页数:7
相关论文
共 32 条
  • [1] A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin
    al-Swayeh, OA
    Clifford, RH
    del Soldato, P
    Moore, PK
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (02) : 343 - 350
  • [2] BILSKY EJ, 1995, J PHARMACOL EXP THER, V273, P359
  • [3] Broom DC, 2000, J PHARMACOL EXP THER, V294, P1195
  • [4] BROOM DC, 2002, IN PRESS PSYCHOPHARM
  • [5] PROBES FOR NARCOTIC RECEPTOR-MEDIATED PHENOMENA .19. SYNTHESIS OF (+)-4-[(ALPHA-R)-ALPHA-((2S,5R)-4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-METHOXYBENZYL]-N,N-DIETHYLBENZAMIDE (SNC-80) - A HIGHLY SELECTIVE, NONPEPTIDE DELTA-OPIOID RECEPTOR AGONIST
    CALDERON, SN
    ROTHMAN, RB
    PORRECA, F
    FLIPPENANDERSON, JL
    MCNUTT, RW
    XU, H
    SMITH, LE
    BILSKY, EJ
    DAVIS, P
    RICE, KC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (14) : 2125 - 2128
  • [6] DIFFERENTIAL ANTAGONISM BY NALTRINDOLE-5'-ISOTHIOCYANATE ON [H-3] DSLET AND [H-3] DPDPE BINDING TO STRIATAL SLICES OF MICE
    CHAKRABARTI, S
    SULTANA, M
    PORTOGHESE, PS
    TAKEMORI, AE
    [J]. LIFE SCIENCES, 1993, 53 (23) : 1761 - 1765
  • [7] CHANG KJ, 1993, J PHARMACOL EXP THER, V267, P852
  • [8] COMER SD, 1993, J PHARMACOL EXP THER, V267, P866
  • [9] COMER SD, 1993, J PHARMACOL EXP THER, V267, P888
  • [10] DYKSTRA LA, 1993, J PHARMACOL EXP THER, V267, P875